BioNTech (NASDAQ:BNTX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of BioNTech (NASDAQ:BNTX) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other analysts have also recently issued reports on BNTX. Citigroup restated a “buy” rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. HC Wainwright raised their target price on shares of BioNTech from $134.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday. BMO Capital Markets raised their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, JPMorgan Chase & Co. cut their target price on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research note on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $138.25.

BioNTech Price Performance

NASDAQ:BNTX opened at $108.49 on Friday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $99.26 and a 200 day simple moving average of $108.40. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a market capitalization of $26.08 billion, a PE ratio of -51.66 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.90 EPS. On average, research analysts expect that BioNTech will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the company. Van ECK Associates Corp grew its holdings in shares of BioNTech by 25.1% during the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company’s stock valued at $13,493,000 after purchasing an additional 23,733 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of BioNTech during the 4th quarter valued at approximately $1,118,000. Vontobel Holding Ltd. grew its holdings in shares of BioNTech by 24.6% during the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company’s stock valued at $2,437,000 after purchasing an additional 4,227 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of BioNTech during the 4th quarter valued at approximately $168,000. Finally, Flossbach Von Storch SE grew its holdings in shares of BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after purchasing an additional 47,236 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.